Effects of dexamethasone implant on macular morphology and visual function in patients with different diseases

PurposeTo evaluate the effects of dexamethasone implant in patients with different retina diseases.MethodsIn the study 194 eyes of patients treated with Dexamethasone implant were included restrospectively in the study. Best‐corrected visual acuity (BCVA) measurement, complete ophthalmic evaluation with Intraocular pressure (IOP), and spectral‐domain optical coherence tomography (OCT) were performed at baseline and 30 days after treatment.ResultsWe have analyzed the results of the administration of dexamethasone implant in 194 eyes, during the years 2015 and 2016. The main indications for the treatment with dexamethasone implant were central retinal oclusion (54.20%), diabetic macular edema (35.35%), Irvine Gass syndrome (4.71%), uveitis (3.03%), macular degeneration (2.02%), vitreous‐ macular traction syndromes (0.33%) and neovascularization of the anterior segment (0.33%). The best visual acuity and the IOP before the administration of dexamethasone implant were respectively 0.21(+/‐ 0.15) and 16 mmHg. After the treatment the best visual acuity improves to 0.27 (+/‐ 0.2) and the IOP was 18.9 mmHg (+/‐6.28). The macular thickness has been reduced to 519.72 micron (+/‐ 157.86) to 429.96 microns (+/‐153.98) after the dexamethasone implant.ConclusionsIntravitreal dexamethasone implant showed an early and fast effect in reducing CRT and moderatly improving BCVA. There are IOP variations, but it rarely exceeds normal limits.